Clinical Trial

Oliceridine for Gastrointestinal Dysfunction

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Gastrointestinal dysfunction is common in patients after major surgery, especially for neurosurgery. It was reported 80% of neurosurgery patients could be combined with gastrointestinal dysfunction, and it may relate to old age, surgery time, and factors of anesthesia and surgery. Meanwhile, postoperative constipation, nausea, and vomiting induced by gastrointestinal dysfunction may increase the intracranial bleeding. Oliceridine could activate mu opioid receptors without the interaction of (beta)arr2-muOR, and may reduce the gastrointestinal dysfunction, but a limited study has illustrated this topic. Thus, this study is conducted to explore whether oliceridine could reduce the gastrointestinal dysfunction vs. sufentanil in patients undergoing neurosurgery.
Trial Details
NCT Number NCT07650812
Lead Sponsor Beijing Tiantan Hospital
Conditions Gastrointestinal Dysfunction
Enrollment 176 participants
Start Date 2026-07-01
Primary Completion 2027-12-15 (estimated)
Study Completion 2027-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-16